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A facile and efficient synthetic route has been developed to substituted benzofuran-2-carboxylate 1,2,3-triazoles for the 
first time by reacting prop-2-yn-1-yl benzofuran-2-carboxylate with a variety of substituted aryl/benzyl azides in DMF/H2O 
system employing standard click reaction. This new method has the lead of good yields, inexpensive reagents, easily 
available, easy work-up, mild reaction conditions, and environmentally friendly reaction conditions. All these compounds 
have been characterized by modern spectral techniques such as IR, 1H NMR, and mass spectroscopy, etc. Evaluation of 
synthesized compounds for antimicrobial activity against specific bacterial strains like Staphylococcus aureus, 
Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa along with antifungal activity against Aspergillus niger and 
Sclerotium rolfsii have been carried out. 
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Infections caused by the microorganisms are a severe 
challenge to the therapeutic area and show up the 
importance and urgent need for new, more effective 
and selective antimicrobial agents. In this regard, 
heterocyclic ring systems have emerged as powerful 
scaffolds for many biological evaluations1. 
Heterocyclic compounds take up a central position in 
organic chemistry and these are an essential part of 
the chemical and life sciences2-4. These compounds 
play an important role in the design and discovery of 
new pharmacologically active molecules5. These are 
of particular interest and significant importance in the 
search for new bioactive molecules in both the 
agrochemical and pharmaceutical industries. 
In this context, oxygen containing heterocyclic 
derivatives exhibit diverse biological and 
pharmacological activities6. Benzofuran is a 
heterocyclic compound consisting of fused benzene 
and furan ring. Benzofurans occur in a great number 
of natural products. Many of the natural benzofurans 
have physiological, pharmacological and toxic 
properties. Benzofurans nucleus presents in various 
synthetic as well as natural compounds and have 
diverse biological and potential applications7. 
Benzofuran and its derivatives are central 
pharmacophores and privileged structures in 
medicinal chemistry. Benzofuran scaffolds have 
drawn considerable attention due to their intense 
chemotherapeutic properties as well as their prevalent 
occurrence in nature8. Benzofuran derivatives are 
versatile agents that can be used to design and 
develop new biologically active agents9. Benzofuran 
derivatives display potent biological properties 
including antimicrobial10, antihyperglycemic11, 
analgesic12, antiparasitic13, antitumor and kinase 
inhibitor14,15 activities. Recently, benzofurans 
derivatives exhibited potent cytotoxic activities 
against human breast cancer cells and ovarian cancer 
cells16,17. The most prominent benzofuran compounds 
are amiodarone, angelicin, xanthotoxin, bergapten, 
nodekenetin and usnic acid. Thus, benzofuran core 
structure can be taken as lead compounds for the 
synthesis of new derivatives with a range of 
biological activities. 
Hence we plan to couple the benzofuran nucleus 
with 1,2,3- triazole moiety and screen for their 
antimicrobial activities. 1,2,3-Triazole substituted 
derivatives have received considerable attention 
during last few decades as they are endowed with 
variety of biological activities and have wide range of 
therapeutic properties. When one biologically active 
derivative is connected to another active moiety, the 
resultant molecule generally has increased potency. 
Hence in the present study the two pharmacophores, 




i.e. benzofuran 1,2,3- triazole moieties are connected 
to obtain potentially more effective, specific and less 
toxic antimicrobial agents.  
 
Results and Discussion 
 
Chemistry 
Initially the intermediate, prop-2-yn-1-yl 
benzofuran-2-carboxylate (4a- b) was synthesized by 
a three step procedure, Further the intermediate was 
converted to 1,2,3-triazoles employing substituted 
aryl azides and benzyl azides as substrates. For the 
preparation of intermediate (4a- b) salicylaldehydes 
(1a-b) on reaction with ethyl bromoacetate in the 
presence of base in acetonitrile as solvent at reflux 
temperature obtained ethyl benzofuran-2-carboxylate 
(2a-b) in 86% yield18. 
It was treated with sodium hydroxide in ethanol 
under heating conditions to obtain the corresponding 
acid (3a-b) in 82% yield19. This benzofuran-2-
carboxylic acid subjected to thionylchloride reaction 
followed by propargylation in presence of base in 
dichloromethane as a solvent at 0°C to obtain key 
intermediate prop-2-yn-1-yl benzofuran-2-carboxylate 
(4a-b) in 75% yield20 (Scheme I). 
This intermediate compound (4a-b) converted to 
corresponding 1,2,3-triazoles employing standard click 
reaction conditions i.e. substituted Aryl azides and 
benzyl azides in presence of catalytic system 
CuSO4·5H2O–sodium ascorbate and DMF–H2O (1 : 1) 
as a solvent at RT provided (1-phenyl-1H-1,2,3-triazol-
4-yl)methyl benzofuran-2-carboxylates (5a-d and 6a-i) 
in 75-80% yields (Scheme II). 
The structures of 5a-b and 6a-i were proved by the 
spectral analysis. In the 1H NMR spectrum of 
compound 5b a characteristic signal at δ 8.14, singlet 
(1H, triazole-H) and 2.42, singlet (3H, –CH3) were 
observed. The 13C NMR spectrum of 5b showed 
signals at δ 144.88, 21.08 ppm which were in the 
agreement with the proposed structure; the mass 





Antibacterial Activity by Paper Disc Method 
In this study, we determined in vitro antibacterial 
activity against two gram positive bacteria 
Staphylococcus aureus(MTCC-96), Bacillus subtilis 
and two gram negative bacteria  
Escherichia coli (MTCC-443), Pseudomonas 
aeruginosa (MTCC-424), Klebsiella pneumonia by the 
cup-plate agar diffusion method 1 at different 
concentrations (1 mg /mL). (Table I, Figure 1) displays 
the inhibition zone diameters for the tested bacteria and 
Norfloxacin and Ofloxacin served as control21. 
The investigation of the antimicrobial screening 
data along with the statistical analysis shown in 
Table I revealed that the synthesized compounds 
showed promising results against the microorganisms. 
Compounds 6g, 6h and 6i expressed the best 
antibacterial activity compared with other synthesized 
derivatives, with inhibition zone diameters 8, 9 and 10 
mm against the tested bacteria except Pseudomonas 
aeruginosa (MTCC-424). As shown in Table I, for 
gram negative bacteria Escherichia coli (MTCC-443), 
compound 6i acts as the most effective one and is 
mostly comparable to the effectiveness of the control 
with zone of inhibition 10 mm.  
According to the inhibition zone diameter results 
and compound structures in Table I, the antimicrobial 
activity against tested bacteria depended on chemical 
structure. Different structure of compounds exhibited 
varied bioactivity. Overall, the compounds with chloro 
substituent on benzofuran and benzene ring exhibited 
significant bioactivity. The compounds that exhibited 
 
Scheme I — Synthesis of key intermediate prop-2-yn-1-yl 
benzofuran-2-carboxylate 4a-b 
 
Scheme II — Synthesis of novel (1-phenyl-1H-1,2,3-triazol-4-
yl)methyl benzofuran-2-carboxylates (5a-b and 6a-i). 




the most bioactivity were those with chloro substituent 
on benzofuran ring. The electron-withdrawing group (-
Cl) contributed remarkably to the bioactivity. These 
findings suggest that the new benzofuran-2-carboxylate 




The antifungal activity of substituted benzofuran-2-
carboxylate 1,2,3-triazoles derivatives (Table II, 
Figure 2) have been evaluated against Aspergillus 
niger and Sclerotium rolfsii by employing 
Ketoconazole as the standard drug concentration of 
1.0 mg/mL22,23. The antifungal activity of compounds 
5b, 6a, 6c, 6d and 6e revealed good zone of 
inhibition, with inhibition zone diameters 4, 4, 4, 4 
and 3 mm against the tested against Sclerotium rolfsii. 
The electron donating groups such as methyl, 
methoxy, chloro, aryl and benzyl substituted groups 
showed better antifungal activity also electronegative 
 
 




fluorine containing analogues showed good activity. 
Whereas the other compounds were showing 
moderate activity against the fungal strains. The most 
compounds exhibited bioactivity when compounds 
with chloro substituent on benzofuran ring. These 
findings suggest that the new benzofuran-2-
carboxylate 1,2,3-triazole compounds exhibit a broad 
spectrum of anti-fungal activity. 
Experimental Section 
All the chemicals used in this study were purchased 
from different commercial sources from Indian 
vendors with more than 99% purity and were used 
without any further purification. Reactions were 
monitored on TLC with UV detection. Final 
purification was carried out using silica gel 60-120 
mesh. The1H and 13C NMR spectra were recorded on 
500, 400, 125 and 100 MHz, respectively, and TMS 
was used as an internal standard. Chemical shifts 
relative to TMS as internal standards were reported as 
δ values in ppm. Mass spectra were recorded using 
electron spray ionization on Waters e2695 Separators 
module (Waters, Milford, MA, USA) mass 
spectrometer. IR spectra were recorded on a Fourier 
transform (FT-IR), USA (Perkin-Elmer model 337) 
instrument. The melting points were determined on a 
Barnstead Electro Thermal 9200 Instrument. 
 
General procedure for the synthesis of ethyl 
benzofuran-2-carboxylate, 2a-b 
To a solution of salicylaldehyde 1a (1mmol)  
in acetonitrile (100 mL), K2CO3 (3.0mmol) and the 
α-bromo ester (1.2mmol) was added slowly to 
reaction mixture at ambient temperature. The 
reaction mixture refluxed for 24 hours. After 
completion of the reaction (monitored by TLC), the 
solvent was removed under reduced pressure. The 
resultant crude product was dissolved in ethyl 
acetate (200 mL) and the resultant solution was 
washed with 5% dil. HCl. The organic layer was 
washed with water (50 mL), brine solution (50 mL) 
and dried over anhydrous sodium sulphate. The 
crude product was purified by column 
chromatography over 60-120 mesh silica gel and 
eluted with ethyl acetate: hexane 1:10 to give title 
compound 2a as off white solid 86%yield. 
 
General procedure for the synthesis of 
benzofuran-2-carboxylic acid, 3a-b 
Ethyl benzofuran-2-carboxylate 2a was dissolved 
in 80 mL of ethanol and the reaction mixture was 
cooled to 10°C. To this cooled mixture, a solution of 
KOH (2.0 mmol) was added drop-wise. After 
completion of the addition, the resulting mixture was 
refluxed for 2-3 hours. Excess ethanol was removed 
under reduced pressure. A light off white solid was 
obtained to which aqueous HCl was (30 mL) was 
added. The solid precipitate was collected by filtration 
and washed with water (50 mL), followed by column 
chromatography over 60-120 mesh silica gel and 
 
Figure 1 — Antibacterial activity of compounds 5a-d and 
6a-6i against Pseudomonas aeruginosa, Echerichia coli,
Staphylococcus aureus and Bacillus subtilis.Micro organisms
were screened using potato dextrose agar with Pseudomonas
aeruginosa, Echerichia coli, Staphylococcus aureus and Bacillus 
subtilis are showing zone of inhibition (mm) with different
concentration of compound. 
 
 
Figure 2 — Antifungal activity of compounds 5a-d and 6a-i 
against Aspergillusniger and Sclerotium rolfsii  
 




eluted with ethyl acetate : hexane 3:7 to give title 
compound 3a as off white solid in 82%yield. 
 
General procedure for the synthesis of prop-2-yn-
1-yl benzofuran-2-carboxylate, 4a-b 
A solution of benzofuran-2-carboxylic acid 3a 
(1.0mmol) in SOCl2 (1.0 mmol) was stirred at 90°C 
for 1 hour. After completion of the reaction 
(monitored by TLC), the reaction mixture was cooled 
to 0°C, diluted with CH2Cl2, and triethyl amine  
(1.5 mmol) and propargyl alcohol (1.1 mmol) were 
added. The resulting solution was stirred for 2 hours 
at ambient temperature. After completion of the 
reaction, CH2Cl2 was removed under vacuum; the 
 




residue obtained was diluted with chilled water and 
extracted with Ethyl acetate (2 × 50 mL). The 
combined organic layers were dried over anhydrous 
sodium sulphate, the solvent was removed  
under reduced pressure. The crude product was 
purified by column chromatography using silica gel 
(60–120 mesh) eluting with ethyl acetate and 
petroleum ether (2:8) to afford compound 4a as off 
white solid in 77% yield. 
4a: IR (neat): 3265, 2126, 1725, 1564, 1291, 1172, 
1090, 746 cm−1; 1H NMR (300MHz, CDCl3): δ 7.69 
(d, 1H, J = 7.742 Hz), 7.59 (d, 2 H, J = 6.232 Hz), 
7.47 (dt, 1 H, J = 7.365,1.13 Hz), 7.32 (t, 1 H, J = 
7.365 Hz), 4.98 (d, 2 H, J = 2.266 Hz), 2.57 (t, 1 H, J 
= 2.266 Hz); 13C NMR (100MHz, CDCl3):δ 158.614, 
155.835, 144.579,127.921, 126,762, 123.877, 
122.906, 114.834, 112.380, 75.605, 52.709; ESI-MS: 
m/z [M + 1] + 200.94. 
4b: IR (neat): 3260, 2132, 1727, 1558, 1275, 1170 
cm−1; 1H NMR (500MHz, CDCl3): δ 7.67 (d, 1H, J = 
2.28 Hz), 7.52 (d, 2 H, J = 9.003 Hz), 7.42 (dd, 1 H, J 
= 8.697,1.984 Hz), 4.98 (d, 2 H, J = 2.441 Hz), 2.58 
(t, 1 H, J = 2.441 Hz); 13C NMR (125MHz, CDCl3):δ 
158.198, 154.080, 145.842, 129.572, 128.278, 
127.967, 122.270, 114.003, 113.453, 76.820, 75.781, 
52,889; ESI-MS: m/z [M + 2] +236.6. 
 
General procedure for the synthesis of (1-phenyl-
1H-1,2,3-triazol-4-yl)methyl benzofuran-2-
carboxylate5a-d and 6a-i 
Prop-2-yn-1-yl benzofuran-2-carboxylate 4a 
(1mmol) and the corresponding aryl or alkyl azides 
(1.1 mmol) were dissolved in 4 mL of a mixture 
DMF–H2O (3 : 1). The reaction mixture was stirred at 
RT for 10 min, then CuSO4·5H2O (0.1 mmol) and 
sodium ascorbate (0.2 mmol) were added. The 
reaction mixture was stirred at ambient temperature 
for 6-8 hours. After completion of the reaction 
(monitored by TLC) add 5 mL of water filtered off 
the crude solid followed by column chromatography 
using silica gel (60–120 mesh) eluting with ethyl 
acetate and petroleum ether (3:7) to afford compound 
5a as off white to brown solid in 78% yield. 
5a: IR (neat):3147, 1720, 1502, 1292, 1171, 748 
cm−1; 1H NMR (500MHz, CDCl3): δ 8.19 (s, 1 H), 
7.75 (d, 2 H, J = 7.934 Hz), 7.68 (d, 1 H, J = 7.782 
Hz), 7.61-7.56 (m, 2 H), 7.53 (t, 2 H, J = 7.782 Hz), 
7.45 (t, 2 H, J = 7.782 Hz), 7.31 (t, 1 H, J = 7.477 
Hz), 5.61(s, 2 H); 13C NMR (100MHz, CDCl3):δ 
159.476, 155.832, 144.852, 143.040, 136.827, 
129.772, 128.970, 127.871, 126.799, 123.874, 
122.927, 122.600, 120.645, 114.678, 112.344, 58.324; 
ESI-MS: m/z [M + 1] + 320.29. 
5b: IR (neat): 3143,1726, 1520, 1294, 1175, 1094, 
750 cm−1; 1H NMR (300MHz, CDCl3): δ 8.14 (s, 1 
H), 7.68 (d, 1 H, J = 7.742 Hz), 7.63-7.55 (m, 4 H), 
7.45 (t, 1 H, J = 7.176 Hz), 7.35-7.27 (m, 3 H), 5.61(s, 
2 H), 2.42 (s, 3 H); 13C NMR (100MHz, CDCl3):δ 
159.482, 155.824, 144.884, 139.123, 134.548, 
130.253, 127.849, 126.807, 123.862, 122.922, 
122.587, 120.535, 114.647, 112.346, 58.363, 21.086; 
ESI-MS: m/z [M + 1] + 334.08. 
5c: IR (neat): 3145, 1724, 1518, 1255, 1175, 
751cm−1; 1H NMR (500MHz, CDCl3): δ 8.09 (s, 1 H), 
7.68 (d, 1 H, J = 7.782 Hz), 7.63 (d, 2 H, J = 8.850 
Hz), 7.61-7.56 (m, 2 H), 7.45 (t, 1 H, J = 7.782 Hz), 
7.31 (t, 1 H, J = 7.477 Hz), 7.02 (d, 2 H, J = 8.850 
Hz), 5.60 (s, 2 H), 3.87 (s, 3 H); 13C NMR (100MHz, 
DMSO-d6):δ 159.248, 158.261, 155.013, 144.465, 
142.270, 129.790, 127.990, 126.480, 123.955, 
123.182, 121.738, 114.743, 114.668, 112.042, 57.954, 
55.429; ESI-MS: m/z [M + 1] + 350.31. 
5d: IR (neat): 3122, 3080, 1730, 1502, 1296, 1175, 
1091, 746 cm−1; 1H NMR (500MHz, CDCl3): δ 8.21 
(s, 1 H), 7.72-7.66 (m, 3 H), 7.60-7.56 (m, 2 H), 7.53-
7.49 (m, 2 H), 7.46 (dt, 1 H, J = 7.354, 0.916 Hz), 
7.31 (t, 1 H, J = 7.324 Hz), 5.61(s, 2 H); 13C NMR 
(100MHz, CDCl3):δ 159.476, 155.847, 144.789, 
135.348, 134.817, 129.986, 127.927, 126.784, 123.913, 
122.943, 121.785, 114.750, 112.353, 58.299; ESI-MS: 
m/z [M + 2] + 355.96. 
6a: IR (neat): 3440, 2977, 2251, 2125, 1658, 1219, 
1051, 1023, 821, 752 cm−1; 1H NMR (500MHz, 
DMSO-d6): δ8.93 (bs, 1 H), 7.96 -7.70 (m, 5 H), 7.62 
-7.34 (m, 3 H), 5.55 (s, 2 H), 2.38 (s, 3 H); 13C NMR 
(100MHz, DMSO-d6):δ; ESI-MS: m/z [M +2] + 370. 
6b:IR (neat): 3440, 2977, 2251, 1659, 1220, 1052, 
1024, 821, 757 cm−1; 1H NMR (400MHz, DMSO-d6): 
δ 8.80 (s, 1 H), 7.95 -7.70 (m, 5 H), 7.56 (bs, 1 H), 
7.14 (bs, 2 H), 5.54 (s, 2 H), 3.84 (s, 3 H); 13C NMR 
(100MHz, DMSO-d6):δ 159.265, 157.909, 153.461, 
145.814, 142.127, 129.765, 128.306, 127.995, 
123.242, 122.453, 121.776, 114.771, 114.095, 
113.846, 58.115, 55.462; ESI-MS: m/z [M + 2] + 386. 
6c: IR (neat): 3439, 2251, 1661, 1051, 1023, 1002, 
821, 759cm−1; 1H NMR (400MHz, DMSO-d6): δ 9.01 
(s, 1 H), 7.98 (d, 2 H, J = 8.925 Hz), 7.90 (d, 1 H, J = 
2.201 Hz), 7.80 (d, 2 H, J = 8.558 Hz),7.70 (d, 2 H, J 
= 8.803 Hz), 7.57 (dd, 1 H, J = 8.925, 2.078 Hz), 5.56 




(s, 2 H); 13C NMR (100MHz, DMSO-d6):δ157.951, 
153.526, 145.844, 142.614, 135.209, 133.112, 
129.847, 128.388, 128.008, 123.431, 122.569, 
121.901, 114.225, 113.912, 58.063; ESI-MS: m/z  
[M + 2] + 389.99. 
6d: IR (neat): 3441, 2251, 1659, 1052, 1024, 821, 
758cm−1; 1H NMR (400MHz, DMSO-d6): δ 8.34 (s, 1 
H), 7.93 -7.67 (m, 3 H), 7.62 -7.21 (m, 6 H), 5.63 (s, 2 
H), 5.44 (s, 2 H); 13C NMR (100MHz, DMSO-d6):δ 
157.953, 153.456, 145.837, 141.429, 135.779, 
128.693, 128.316, 128.124, 127.979, 125.211, 
122.475, 114.043, 113.875, 58.215, 52.793; ESI-MS: 
m/z [M + 2] + 370.03. 
6e: IR (neat):3456, 2979, 2251, 1658, 1220, 1052, 
1024, 821, 748 cm−1; 1H NMR (500MHz, DMSO-d6): 
δ 8.34 (s, 1 H), 7.85 (d, 1 H, J = 1.678 Hz), 7.78 -7.71 
(m, 2 H), 7.54 (dd, 1 H, J = 8.850, 1.984 Hz), 7.45-
7.39 (m, 2 H), 7.21 (t, 2 H, J = 8.850 Hz), 5.60 (s, 2 
H), 5.44 (s, 2 H); 13C NMR (125MHz, DMSO-d6):δ 
162.782, 160.841, 157.936, 153.431, 145.811, 
132.013, 130.358, 130.286, 128.308, 127.977, 
125.209, 122.459, 115.605, 115.438, 114.029, 
113.827, 58.189, 51.993; ESI-MS: m/z [M + 2] + 
388.03. 
6f: IR (neat): 3289, 3147, 3094, 2960, 1733, 1572, 
1449, 1304, 1175cm−1; 1H NMR (400MHz, DMSO-
d6): δ 8.35 (bs, 1 H), 8.0-7.69 (m, 4 H), 7.58 (bs, 1 H), 
7.30 (bs, 1 H), 6.92(bs, 2 H), 5.59(s, 2 H), 5.45(s, 2 
H), 3.74(s, 3 H); 13C NMR(100 MHz, DMSO-
d6):δ159.402, 157.999, 153.514, 141.470, 137.258, 
130.026, 128.372, 128.084, 125.306, 122.658, 120.100, 
114.234, 113.817, 113.498, 58.275, 54.116, 52.758 ; 
ESI-MS: m/z [M + NH3] + 420. 
6g: IR (neat): 3132, 2927, 2861, 1716, 1570, 1451, 
1292, 1177, 821 cm−1; 1H NMR (400MHz, DMSO-
d6): δ 8.29 (bs, 1 H), 7.97-7.66 (m, 3 H), 7.56(bs, 1 
H), 5.45(s, 2 H), 4.38(s, 2 H), 1.80(s, 2 H), 1.25(bs, 6 
H), 0.83(s, 3 H); 13C NMR (100MHz, DMSO-
d6):δ158.167, 153.612, 146.021, 128.506, 128.194, 
125.174, 122.690, 114.216, 113.990, 58.400, 49.528, 
30.585, 29.672, 25.510, 21.954, 13.850; ESI-MS: m/z 
[M + NH3] + 384. 
6h: IR (neat): 3148, 3024, 2344, 2119, 1731, 1574, 
1306, 1176, 767 cm−1; 1H NMR (400MHz, DMSO-
d6): δ8.41 (bs, 1 H), 7.96 -7.69 (m, 5 H), 7.64 -7.50 
(m, 2 H), 7.48-7.31 (m, 1 H), 5.66 (s, 2 H), 5.46  
(s, 2 H); 13C NMR (100MHz, DMSO-d6):δ163.238, 
160.803, 157.950, 153.441, 145.831, 138.456, 
130.838, 128.319, 128.001, 125.397, 124.092, 
122.762, 115.109, 114.893, 114.031, 113.856, 58.197, 
52.089; ESI-MS: m/z [M +1] + 386. 
6i: IR (neat): 3275, 2925, 2858, 1730, 1579, 1488, 
1260, 1173, 768 cm−1; 1H NMR (400MHz, DMSO-
d6): δ 8.36 (bs, 1 H), 7.96-7.67 (m, 3 H), 7.63-7.28 
(m, 4 H), 7.24-6.85 (m, 6 H), 5.63(s, 2 H), 5.45(s, 2 
H); 13C NMR (100MHz, DMSO-d6):δ 157.972, 
156.885, 156.068, 153.472, 145.854, 141.467, 
137.956, 130.428, 130.032, 128.341, 128.022, 
125.365, 123.666, 122.831, 122.489, 118.764, 
117.946, 114.062, 113.900, 58.219, 52.369; ESI-MS: 
m/z [M + 2] + 462. 
 
Conclusion 
In summary, we have developed a new and 
efficient method for the synthesis of substituted novel 
benzofuran-2-carboxylate 1,2,3-triazoles derivatives 
which are of interest in several fields for their 
biological properties and synthetic utility in excellent 
yields using standard Click chemistry method at 
ambient temperature conditions in DMF/H2O media. 
Compared to other methods, this new method has the 
lead of good yields, inexpensive reagents, easily 
available, easy work-up, mild reaction conditions, and 
environmentally friendly reaction conditions. The 
in vitro antibacterial, antifungal evaluation showed 
that most of the synthesized substituted benzofuran-2-
carboxylate 1,2,3-triazoles derivatives exhibited 
moderate to good zone of inhibition. From the results 
of antibacterial and antifungal activity of compounds 
it is interesting to note that substituents like methoxy, 
methyl and fluoro  show better antibacterial and 
moderate antifungal activity compared to other 
substituted compounds. Noticeably, compound 6g, 6h 
and 6i were most potent compounds in vitro against 
bacterial and fungal strains. 
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